Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Verteporfin might reverse severe hair loss but is still in early testing stages. It could be a future option for NW6-7, though expensive.

RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.

User starts Nuclear Stack treatment for hair loss, including Dutasteride, Minoxidil, RU58841, Derminator 2, and supplements. Seeks advice on storing and dosing RU58841.

Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.

The post and conversation are about the high cost and skepticism surrounding pyrilutamide as a hair loss treatment, with comparisons to minoxidil, finasteride, and RU58841. The original poster defends pyrilutamide's effectiveness and criticizes others for dismissing it without proper understanding.

A user is exploring VEGF gene therapy to enhance hair transplant results, considering measuring hair shaft diameter and growth rate. Suggestions include using phototrichograms and possibly adding PRP, though its effectiveness is uncertain.

A user's experience with the Big 3 (minoxidil, finasteride and RU58841) hair loss treatment along with dermarolling. The dermaroller pin was 1.5mm used once per week and drew some blood but not a lot.

VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.

PP405 might make minoxidil unnecessary, but finasteride or other 5AR inhibitors may still be needed. PP405 is expected to be expensive and not available until at least 2028, with limited information on its effectiveness.

Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.

The conversation is about trying PTD-DBM for hair loss treatment. Users are curious about its effectiveness and results.

Kintor is accused of using fake pictures to promote their product, Pyrilutamide (KX826), which failed Phase 3 trials. Users express disappointment and note similar false advertising has occurred with finasteride and minoxidil.

People discussed which is better for hair loss treatment between a dermaroller and a dermastamp, concluding that a dermastamp is better. They also mentioned that a dermaroller can be used for beard growth.

User tries dermapen for hair loss and plans to use non-mainstream topicals like c60, ghk-cu, and ptd-dbm with valproic acid. They also use a head massager and modified LLLT belt for additional treatment.

The conversation is about where to buy RU58841 without propylene glycol. The user also asks if anyone else has tried RU58841.

The conversation discusses skepticism and diminishing excitement around the hair loss treatment PP405 due to unclear trial results. It also mentions other treatments like finasteride, minoxidil, VDPHL01 (extended-release minoxidil), and GT20026 as potential options for hair loss management.

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

The conversation discusses hair regrowth progress using finasteride and minoxidil, with the user switching from topical to oral minoxidil. Some users express skepticism about the progress photos, while others note that younger individuals may respond better to these treatments.

The user reports a stable receding hairline with new hair growth after using 5% minoxidil, 1mg oral finasteride, D-Biotin daily, derma rolling twice a week, and three PRP sessions per month. They plan to update their progress in four months.

The user shared progress after two months using a topical formulation containing Dutasteride 0.25%, Minoxidil 5%, Cetirizine 1%, Melatonin 0.5%, Caffeine 2%, and Latanoprost 0.005%. The focus is on hair loss treatment results.

The conversation is about finding a legitimate source for RU58841 in Germany, with suggestions including Receptorchem and GeneTherica. Anageninc and Chemyo do not deliver to Germany.

Use rosemary oil 2-3 times a week, ideally after derma rolling, for optimal results. This routine can complement other treatments like Minoxidil, finasteride, or RU58841.

Topical minoxidil and dermaroller use showed noticeable hair regrowth in two months and one week. Some users suggest adding finasteride for better results.

The conversation discusses the frustration over the unavailability of 2.5mg dutasteride soft gels, with some users suggesting higher doses for better scalp DHT suppression. Concerns about side effects and the necessity of DHT are debated, with some users advocating for alternative treatments like RU58841 and oral minoxidil.

Exploring the potential of using verteporfin during hair transplants to minimize scarring and regenerate follicles, as well as discussing a possible standardized protocol for this treatment.